FindTrial
Sign In

Carvedilol drug in ACLF Patients (liver disease).

Acute hemodynamiC response To Carvedilol predicts survival in ACLF patients –“ACT - C ACLF study ? - ACT - C ACLF Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/03/064273
Enrollment
100
Registered
2024-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K768- Other specified diseases of liver

Interventions

Intervention1: Nil: Nil

Sponsors

Institute of Liver and Biliary Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18–70 yrs 2. ACLF diagnosis (AARC criteria)

Exclusion criteria

Exclusion criteria: 1. Contraindications to NSBB (Heart rate less than 65 per min, BP less than 110 by 65 mm Hg, Asthma, Heart failure, AKI, Large ascites, SBP, S. Na less than 125) 2. PVT 3. HCC 4. BCS 5. HE grades 2 to 4 6. NSBB therapy within 5 days 7. Pregnancy 8. Lactation 9. Planned for LT in the next 12 weeks 10. No consent.

Design outcomes

Primary

MeasureTime frame
Predictive value of acute HVPG change by carvedilol for 28 day transplant free survival in patients of ACLFTimepoint: Day 28—

Secondary

MeasureTime frame
Complications [PHT related bleed, AKI, infections, HE, Hypotension, Cardiac side effect] within 90 daysTimepoint: 90 days;Correlation with evolution of AARC score by 2 weeksTimepoint: 2 weeks;Transplant-free survival rate at 90 daysTimepoint: 90 days—

Countries

India

Contacts

Public ContactDr Chitranshu vashishtha

Institute of Liver and Biliary Sciences

chitranshuv@gmail.com09540951042

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026